&w=3840&q=100)
150 years from the Banyan Tree: The story of BSE, people who shaped growth
Sachin P Mampatta
Listen to This Article
In some ways, the history of the BSE can be traced back to the speculative mania that gripped Mumbai (then Bombay) more than a decade before the exchange's founding. Among the key figures of that great bubble was Premchand Roychand, described as a 'devout Jain, of fair complexion, lithe of limb and sweet of temper, of engaging manners and free from the pride of riches — who had seen no more than thirty-four summers but who carried a most clever financial head on his shoulders.'
Roychand was involved with financial institutions like the Bank of Bombay and the Asiatic Bank.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a few seconds ago
- Business Standard
Recently listed biotech stock surges 44% against issue price; time to sell?
Anthem Biosciences share price today Shares of Anthem Biosciences (Anthem) surged 9 per cent to ₹820 on the BSE in Thursday's intra-day trade amid heavy volumes after the company reported strong earnings for the quarter ended June 2025 (Q1FY25). The stock price of the Contract Research, Development and Manufacturing Organization (CRDMO) company was trading at the highest level since its listing on July 21, 2025. Anthem Biosciences has zoomed 44 per cent against its issue price of ₹570 per share. At 10:24 AM; the stock was quoting 8 per cent higher at ₹816, as compared to 0.18 per cent rise in the BSE Sensex. The average trading volumes at the counter jumped nearly three-fold. A combined 4.4 million shares changed hands on the NSE and BSE. Q1 results – Anthem For the April to June 2025 quarter (Q1FY26), Anthem reported a 64.8 per cent year-on-year (Y-o-Y) and 64.4 per cent quarter-on-quarter (Q-o-Q) growth in profit after tax at ₹135.8 crore. Revenue from operations grew 59.5 per cent Y-o-Y at ₹540.2 crore. Earnings before interest, taxes, depreciation, amortization (EBITDA) increased 52.7 per cent Y-o-Y at ₹214.3 crore; margins remained flat at 35.4 per cent. Strong Y-o-Y growth in Q1FY26 reflects a CRDMO revenue stream that started ramping up since Q2FY25. A combination of a dedicated team, strategic focus, operational excellence and long-standing client partnerships has helped Anthem to deliver performance across both CRDMO and Specialty Ingredients business, the management said. Brokerages view on Anthem Anthem has built a strong global presence, backed by a significant level of expertise from its founders and management team. It holds a unique position in the industry led by its integrated capabilities to manufacture both small molecules and biologics, coupled with a diverse range of modalities. This has helped it to grow faster than its industry peers while maintaining high profitability and return ratios. Currently, Anthem is working on ~16 projects in their final stages, including 10 late stage molecules. Historically, it has observed 81 per cent of success rate in commercializing its late-stage molecules, which provides confidence in its future growth potential, Nirmal Bang Securities had said in its IPO note. Anthem Biosciences is well positioned to cater in CROs and CRDMO segment the crucial players in the pharmaceutical and biotechnology industries wherein the company being niche player in with high entry barriers through its differentiated FFS model, long term relationship, strong R&D, innovation and technology driven approach across drug discovery, development and manufacturing. The company has shown a profitable track record against its peers and intend to maintain by leveraging its integrated manufacturing and technological capabilities by focusing on building complex speciality ingredients, peptides, probiotics etc, said Anand Rathi Share and Stock Brokers. About Anthem Anthem is an innovation-driven and technology-focused CRDMO with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, Anthem serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
Economic Times
a few seconds ago
- Economic Times
Muthoot Finance gets target price boost from Jefferies and Nuvama. Is it time to buy?
Leading brokerage firms, Jefferies and Nuvama, have raised their target prices on Muthoot Finance following the company's robust Q1FY26 performance. Both firms have reiterated their bullish stance on the non-banking financial company, citing strong growth in gold loan assets, margin expansion, and improved asset quality as key positives. ADVERTISEMENT The newly assigned target prices reflect a healthy 19% upside in the stock from its closing price on Wednesday. Additionally, after the results, the stock surged 11.3% to its new 52-week high of Rs 2,793.65 on the BSE. Jefferies has maintained its 'Buy' rating on Muthoot Finance while increasing its target price to Rs 2,950 from Rs 2,660, valuing the stock at 2.7x September 2027 estimated book value. The brokerage highlighted the company's 90% YoY growth in standalone profit to Rs 2,046 crore, driven by strong gold loan growth, margin expansion, and NPA to Jefferies, Muthoot Finance's Q1 performance benefited from a favourable macro environment for gold loans, with AUM up 42% YoY and loan-to-value (LTV) ratios offering headroom for further growth. Margins improved sequentially, with the net interest margin (NIM) rising by 88 basis points to 12.2%. This was aided by recoveries totalling Rs 3.5 billion, including Rs 1 billion from asset reconstruction companies, and the rest from non-performing loan settlements. ADVERTISEMENT The brokerage also noted that while loans are largely fixed-rate, about half of borrowings are floating and mostly linked to MCLR, implying some lag in cost repricing. Jefferies expects Muthoot to deliver a 23% profit CAGR with return on equity (ROE) exceeding 21% over FY26–28, supported by steady loan growth, controlled credit costs, and limited loan losses. Unlock 500+ Stock Recos on App ADVERTISEMENT Nuvama has also reiterated its 'Buy' recommendation, raising its target price to Rs 2,993 from Rs 2,625, based on a 3.4x FY26 estimated book value. The brokerage described Muthoot's Q1FY26 as a 'strong all-round beat,' significantly outperforming peers across growth, profitability, and asset quality pointed out that consolidated AUM rose 10% QoQ and 42% YoY, with gold AUM alone growing 40% YoY and 10% QoQ. Margins expanded by 88 basis points sequentially, aided by recoveries from both NPL settlements and ARC transactions. Even excluding recoveries, yields remained steady, unlike the declines seen among other lenders in the sector. ADVERTISEMENT The brokerage also highlighted the company's efficient cost management and significant reduction in credit costs during the quarter. Recoveries of Rs 3.5 billion, including Rs 1 billion from ARC sales, directly contributed to yield improvement. Additionally, subsidiaries' growing contribution to the gold loan business is expected to support overall momentum. Nuvama added that management remains confident in sustaining both yield and growth levels going Finance on Wednesday reported a consolidated net profit of Rs 1,974 crore for the quarter ended June 30, 2025, up 65% from Rs 1,196 crore in the corresponding period last year. ADVERTISEMENT Sequentially, profit rose 37% from Rs 1,444 crore in Q4FY25. The lender's consolidated loan assets under management (AUM) reached a record Rs 1,33,938 crore, representing a 37% year-on-year increase and a 10% rise from the previous loan AUM, a key business segment for the company, grew 40% YoY to Rs 1,13,194 crore, marking its highest annual growth in this segment to company also reported other operational highlights during the quarter, including crossing the Rs 1 trillion market capitalisation milestone, opening 22 new branches, and winning six awards at the E4M Golden Mikes, such as the Golden Category award for Best Integrated TV Campaign and the Silver Category award for Best Use of Influencers/Celebrities on TV for its 'Sunheri Soch' Season 3 campaign. Also read: Zerodha's Nithin Kamath on how a boring, invisible Sebi step brought windfall gains for retail investors (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
Mint
a few seconds ago
- Mint
Vodafone Idea share price cracks 4% to hit 52-week low ahead of Q1 results today
Vodafone Idea share price declined nearly 4% in early trade on Thursday, ahead of the announcement of its Q1 results 2025. Vodafone Idea shares slumped as much as 3.92% to hit a fresh 52-week low of ₹ 6.12 apiece on the BSE. The Aditya Birla Group telecom operator is set to declare its financial results for the first quarter of FY26 today, August 14. Vodafone Idea Q1 results are expected to highlight the continued financial stress with increasing losses on a year-on-year (YoY) basis, while revenue is expected to grow marginally amid improved subscriber mix and a slight uptick in Average Revenue Per User (ARPU). Here's what to expect from Vodafone Idea Q1 results 2025: Vodafone Idea's net loss in the first quarter of FY26 is expected to widen to ₹ 7,145 crore from a loss of ₹ 6,432 crore in the corresponding quarter of previous fiscal year, according to estimates by JM Financial. The telco has posted a net loss of ₹ 7,166 in the quarter ended March 2025. The company's revenue in Q1FY26 is estimated to grow 6% to ₹ 11,135 crore from ₹ 10,508 crore, year-on-year (YoY). Revenue is expected to rise 1.1% from ₹ 11,013 crore on a sequential basis. JM Financial estimates Vodafone Idea's ARPU in the quarter ended June 2025 to improve to ₹ 167 from ₹ 164, QoQ, due to upgrades and improved subscriber mix and aided by 1 more day QoQ in Q1FY26, while July 2024 tariff hike has completely passed through its APRU by end Q3FY25. At the operational level, reported EBITDA is expected to be higher 1.8% QoQ at ₹ 4,741 crore and Pre-IND AS EBITDA (or cash EBITDA) to be higher 3.5% QoQ at ₹ 2,402 crore in the June quarter. Motilal Oswal Financial Services (MOFSL) expect Vodafone Idea to report flat QoQ wireless revenue on account of continued subscriber base declines, offset by a slight uptick in ARPU. It expects reported EBITDA to decline 2% QoQ, with EBITDA margin contracting by 80 basis points (bps) QoQ to 41.5%. ARPU is likely to increase 1% QoQ to ₹ 165, while the EoP subscriber base is expected to decline ~1.2 million, MOFSL said, expecting capex of ₹ 3,600 crore. Vodafone Idea share price has fallen 18% in one month and more than 10% in three months. The telecom stock has declined 24% over the past six months and has dropped 22% on a year-to-date (YTD) basis. Vodafone Idea shares have crashed 60% in the past one year. At 11:10 AM, Vodafone Idea share price was trading 1.73% lower at ₹ 6.26 apiece on the BSE. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
